Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-26113100 in moderate atopic dermatitis
NCT00455429Phase 2Terminated
- Sponsor
- Johnson & Johnson
- Start
- Apr 2007
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JNJ-26113100 in atopic dermatitis (AD), sponsored by Johnson & Johnson. Started Apr 2007; status: terminated.
02
Drugs
JNJ-26113100
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT00455429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00455429.